Onderzoek naar de werkzaamheid van toevoeging van Cetuximab aan de combinatie van radiotherapie en Cisplatin bij patiënten met niet-kleincellig longkanker.

Recruiting

• Conditions: Cetuximab, non-small lung carcinoma, cisplation, radiotherapy, locally advanced

• Registration Number: NL-OMON21439
• Lead Sponsor: KI-AV

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 110

Inclusion Criteria

1. >= 18 years of age;

2. Histologically or cytologically confirmed diagnosis of NSCLC;

Exclusion Criteria

1. Concurrent active malignancy other than localized, non-melanoma skin cancer or carcinoma-in-situ of the cervix (unless definitive treatment was completed 5 years or more before study entry and the patient has remained disease free);

2. Prior:

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The clinical activity of Cetuximab CCRT locally advanced NSCLC (as defined by the objective rate of local control (OLRC)).

Secondary Outcome Measures

Name	Time	Method
1. The safety profile of Cetuximab in combination with concurrent chemo-radiotherapy;<br /><br>2. Overall survival (OS);<br /><br>3. Progression free survival (locoregional/distant) (PFS);<br /><br>4. Duration of overall response;<br /><br>5. Response duration;<br /><br>6. Adverse events.